Celyad Stock Price, News & Analysis (NASDAQ:CYAD)

$40.30 2.55 (6.75 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$37.75
Today's Range$40.02 - $41.12
52-Week Range$16.73 - $64.75
Volume3,264 shs
Average Volume2,730 shs
Market Capitalization$372.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Celyad (NASDAQ:CYAD)

Celyad logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CYAD
CUSIPN/A
Phone+32-10-394100

Debt

Debt-to-Equity Ratio0.01%
Current Ratio5.53%
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.43 million
Price / Sales42.18
Cash FlowN/A
Price / CashN/A
Book Value$10.81 per share
Price / Book3.73

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees88
Outstanding Shares9,870,000

Celyad (NASDAQ:CYAD) Frequently Asked Questions

What is Celyad's stock symbol?

Celyad trades on the NASDAQ under the ticker symbol "CYAD."

Where is Celyad's stock going? Where will Celyad's stock price be in 2017?

1 Wall Street analysts have issued 12 month target prices for Celyad's shares. Their forecasts range from $74.00 to $74.00. On average, they anticipate Celyad's share price to reach $74.00 in the next year. View Analyst Ratings for Celyad.

Who are some of Celyad's key competitors?

Who are Celyad's key executives?

Celyad's management team includes the folowing people:

  • Michel E J Lussier, Chairman of the Board, Co-Founder (Age 52)
  • Christian Homsy MD, Member of the Executive Management Committee, Chief Executive Officer, Executive Director (Age 57)
  • Patrick Jeanmart, Member of the Executive Management Committee, Chief Financial Officer (Age 43)
  • Gaetane Metz, Chief Operating Officer
  • Richard Mountfield, Vice President of Global Regulatory Affairs
  • Peter De Waele, Member of the Executive Management Committee, Vice President - Research & Development (Age 56)
  • Georges Rawadi, Vice President - Business Development
  • Seron Aymeric, Program Manager
  • Philippe Dechamps, Chief Legal Officer
  • Roland Gordon-Beresford Ph.D., Regulatory Affairs and IP Director

When did Celyad IPO?

(CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Who owns Celyad stock?

Celyad's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (3.42%). View Institutional Ownership Trends for Celyad.

Who sold Celyad stock? Who is selling Celyad stock?

Celyad's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Celyad.

How do I buy Celyad stock?

Shares of Celyad can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celyad's stock price today?

One share of Celyad stock can currently be purchased for approximately $40.30.

How big of a company is Celyad?

Celyad has a market capitalization of $372.51 million and generates $9.43 million in revenue each year. Celyad employs 88 workers across the globe.

How can I contact Celyad?

Celyad's mailing address is Rue Edouard Belin 12, MONT-SAINT-GUIBERT, 1435, Belgium. The company can be reached via phone at +32-10-394100.


MarketBeat Community Rating for Celyad (CYAD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Celyad and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celyad (NASDAQ:CYAD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $74.00$74.00$49.00$95.00
Price Target Upside: 20.92% upside20.92% upside9.50% upside62.48% upside

Celyad (NASDAQ:CYAD) Consensus Price Target History

Price Target History for Celyad (NASDAQ:CYAD)

Celyad (NASDAQ:CYAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$74.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Earnings History for Celyad (NASDAQ:CYAD)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Celyad (NASDAQ:CYAD) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.22 EPS
Next Year EPS Consensus Estimate: $-3.06 EPS

Dividends

Dividend History for Celyad (NASDAQ:CYAD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celyad (NASDAQ CYAD)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Celyad (NASDAQ CYAD) News Headlines

Source:
DateHeadline
Celyad (CYAD) Downgraded by ValuEngine to "Sell"Celyad (CYAD) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 5:12 PM
Zacks: Analysts Set $74.00 Price Target for Celyad SA (CYAD)Zacks: Analysts Set $74.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - November 28 at 11:24 PM
Celyad to Present at the 29th Annual Piper Jaffray Healthcare ConferenceCelyad to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 6:01 PM
Celyad: Why Did It Go Down Recently? - Seeking AlphaCelyad: Why Did It Go Down Recently? - Seeking Alpha
seekingalpha.com - November 17 at 11:34 PM
Celyad Announces Third Quarter 2017 Business UpdateCelyad Announces Third Quarter 2017 Business Update
finance.yahoo.com - November 17 at 1:25 PM
NKTRs Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave RisesNKTR's Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave Rises
www.rttnews.com - November 13 at 10:43 PM
 Analysts Set $74.00 Price Target for Celyad SA (CYAD) Analysts Set $74.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - November 11 at 1:28 AM
Zacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by BrokeragesZacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 7 at 5:32 AM
NovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD) Financial ReviewNovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD) Financial Review
www.americanbankingnews.com - November 4 at 8:22 AM
Edison Issues ADR Update on Celyad (CYAD)Edison Issues ADR Update on Celyad (CYAD)
finance.yahoo.com - October 30 at 6:22 PM
Zacks: Celyad SA (CYAD) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Celyad SA (CYAD) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - October 17 at 10:48 AM
Celyad SA (CYAD) Rating Reiterated by Piper Jaffray CompaniesCelyad SA (CYAD) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - October 9 at 1:22 PM
Celyad SA (CYAD) Reports First Complete Response in Relapsed Refractory AML Patient in THINK Trial - StreetInsider.comCelyad SA (CYAD) Reports First Complete Response in Relapsed Refractory AML Patient in THINK Trial - StreetInsider.com
www.streetinsider.com - October 3 at 7:38 AM
Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trialCelyad reports a first complete response in a relapsed refractory AML patient in the THINK trial
finance.yahoo.com - October 3 at 7:38 AM
 Brokerages Set $49.00 Price Target for Celyad SA (CYAD) Brokerages Set $49.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - October 1 at 10:22 AM
Celyad to Present at the Cantor Fitzgerald Global Healthcare ConferenceCelyad to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:30 PM
Reviewing Celyad SA (CYAD) & TG Therapeutics (TGTX)Reviewing Celyad SA (CYAD) & TG Therapeutics (TGTX)
www.americanbankingnews.com - September 11 at 10:40 AM
 Analysts Set $49.00 Price Target for Celyad SA (CYAD) Analysts Set $49.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - September 8 at 4:44 AM
Celyad SA :CYAD-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017Celyad SA :CYAD-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017
finance.yahoo.com - September 5 at 7:20 PM
Celyad SA (CYAD) Stock Rating Reaffirmed by Piper Jaffray CompaniesCelyad SA (CYAD) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - September 4 at 9:26 PM
Celyad Reports First Half 2017 Financial Results and Operational ProgressCelyad Reports First Half 2017 Financial Results and Operational Progress
finance.yahoo.com - August 29 at 3:36 AM
Celyad SA (CYAD) Scheduled to Post Quarterly Earnings on TuesdayCelyad SA (CYAD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 22 at 2:20 AM
Edison Issues Update on Celyad (CYAD)Edison Issues Update on Celyad (CYAD)
finance.yahoo.com - August 14 at 6:03 PM
Celyad announces new agreements with Celdara Medical and Dartmouth CollegeCelyad announces new agreements with Celdara Medical and Dartmouth College
finance.yahoo.com - August 4 at 6:04 AM
 Celyad SA (NASDAQ:CYAD) Receives Average Rating of "Strong Buy" from Analysts Celyad SA (NASDAQ:CYAD) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - August 3 at 8:48 PM
Celyad SA (CYAD) Initiates SHRINK Trial With CYAD-01Celyad SA (CYAD) Initiates SHRINK Trial With CYAD-01
www.streetinsider.com - July 21 at 5:50 AM
Celyad SA (CYAD) Initiates SHRINK Trial With CYAD-01 - StreetInsider.comCelyad SA (CYAD) Initiates SHRINK Trial With CYAD-01 - StreetInsider.com
www.streetinsider.com - July 20 at 7:46 PM
Celyad announces initiation of the SHRINK trialCelyad announces initiation of the SHRINK trial
finance.yahoo.com - July 20 at 4:51 AM
Celyad: Some Questions For ManagementCelyad: Some Questions For Management
seekingalpha.com - July 8 at 10:05 AM
Celyad SA (CYAD) Announces Early Results at First Dose Level of Solid Arm of THINK TrialCelyad SA (CYAD) Announces Early Results at First Dose Level of Solid Arm of THINK Trial
www.streetinsider.com - June 19 at 1:56 PM
Celyad SA (CYAD) Receives Additional US Patent for Cancer Treatment based on TCR-deficient CAR-T CellsCelyad SA (CYAD) Receives Additional US Patent for Cancer Treatment based on TCR-deficient CAR-T Cells
www.streetinsider.com - May 30 at 11:47 AM
Celyad SA (CYAD) Granted FDA Fast Track Status for C-CureCelyad SA (CYAD) Granted FDA Fast Track Status for C-Cure
www.streetinsider.com - May 11 at 10:15 PM
Celyad SA: Notice of Extraordinary General Meeting to be held on the 12 June 2017Celyad SA: Notice of Extraordinary General Meeting to be held on the 12 June 2017
www.businesswire.com - May 11 at 2:47 AM
Celyad SA (CYAD) Says DFA Authorized Initiation Of THINK Trial in ... - StreetInsider.comCelyad SA (CYAD) Says DFA Authorized Initiation Of THINK Trial in ... - StreetInsider.com
www.streetinsider.com - March 8 at 5:23 PM
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK TrialCelyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
us.rd.yahoo.com - February 16 at 1:47 PM
Celyad SA (CYAD) Reports Activation of Second Site in Belgium for ... - StreetInsider.comCelyad SA (CYAD) Reports Activation of Second Site in Belgium for ... - StreetInsider.com
www.streetinsider.com - January 13 at 3:04 AM
Celyad SA (CYAD) Reports Activation of Second Site in Belgium for THINK TrialCelyad SA (CYAD) Reports Activation of Second Site in Belgium for THINK Trial
www.streetinsider.com - January 12 at 10:02 PM
Celyad Announces Registration of the first patient in the Belgian THINK trialCelyad Announces Registration of the first patient in the Belgian THINK trial
us.rd.yahoo.com - January 5 at 3:42 AM
CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual MeetingCELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
us.rd.yahoo.com - December 7 at 9:37 AM
3:54 am Celyad SA presents new data from its CAR-T NKR-2 Phase I Trial; demonstrates strong safety signals, including no cases of cytokine release syndrome3:54 am Celyad SA presents new data from its CAR-T NKR-2 Phase I Trial; demonstrates strong safety signals, including no cases of cytokine release syndrome
us.rd.yahoo.com - December 7 at 9:37 AM
CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting - GlobeNewswire (press release)CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting - GlobeNewswire (press release)
globenewswire.com - December 6 at 11:40 AM
Celyad SA (CYAD) Receives Approval in Belgium to Commence NKR-2 CAR-T Clinical Trial - StreetInsider.comCelyad SA (CYAD) Receives Approval in Belgium to Commence NKR-2 CAR-T Clinical Trial - StreetInsider.com
www.streetinsider.com - November 21 at 9:29 AM
Celyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016Celyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016
www.streetinsider.com - November 7 at 11:14 PM
Celyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016 - StreetInsider.comCelyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016 - StreetInsider.com
www.streetinsider.com - November 7 at 4:18 PM

SEC Filings

Celyad (NASDAQ:CYAD) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Celyad (NASDAQ:CYAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celyad (NASDAQ CYAD) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.